 |
|
|
|
|
|
|
| |
|
ITT解析群 |
|
インフルエンザ陽性者群 |
|
高リスク群 |
|
|
|
|
|
|
|
| |
|
| n |
プラセボ
中央値 |
実薬
中央値 |
差
(95% CI) |
|
|
| n |
プラセボ
中央値 |
実薬
中央値 |
差
(95% CI) |
|
|
| n |
プラセボ
中央値 |
実薬
中央値 |
差
(95% CI) |
|
|
|
|
|
|
|
|
|
|
|
| 455 |
6.5 |
5.0 |
1.5
(0.5 to 2.25)
p＝0.011
|
|
|
| 321 |
6.0 |
4.5 |
1.5
(0.5 to 2.25)
p＝0.004 |
|
|
| 76 |
8.0 |
5.5 |
2.5
(−1.0 to 8.0)
p＝0.048 |
|
|
|
|
|
|
|
|
|
|
|
| 777 |
6.0 |
5.5 |
0.5
(−0.5 to 1.0)
p＝0.228
|
|
|
| 569 |
6.0 |
5.0 |
1.0
(0.5 to 1.5)
p＝0.078
|
|
|
| 109 |
6.5 |
7.5 |
＋1
(CI not given)
p＝0.710
|
|
|
|
|
|
|
|
|
|
|
|
| 356 |
7.5 |
5.0 |
2.5
(0.75 to 3.5)
p＜0.0001
|
|
|
| 277 |
7.5 |
5.0 |
2.5
(1.0 to 4.0)
p |
|
|
| 32 |
11.5 |
9.0 |
2.5
(CI not given)
p＝0.178
|
|
|
|
|
|
|
|
|
|
|
|
1588
|
6.0 |
5.0 |
1.0
(0.5 to 1.5)
p＜0.001
|
|
|
| 1167 |
6.5 |
5.0 |
1.5
(1.0 to 2.0)
p＜0.001
|
|
|
| 217 |
8.0 |
6.0 |
2
(95％ CI-0.5
to 4.25)
p＝0.127
|
|
|
|
|
|
|
|
|